[1]贾英丽,刘坤,王英丽,等.健脾祛瘀法治疗Ⅲ/Ⅳ期胃癌疗效观察[J].西部中医药,2022,35(07):58-60.[doi:10.12174/j.issn.2096-9600.2022.07.15]
　JIA Yingli,XU Yueze,LIU Kun,et al.Observation on Clinical Effects of Invigorating-spleen Removing-stasis Method in the Treatment of Stage Ⅲ/Ⅳ Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2022,35(07):58-60.[doi:10.12174/j.issn.2096-9600.2022.07.15]
点击复制

健脾祛瘀法治疗Ⅲ/Ⅳ期胃癌疗效观察
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年07期
页码:
58-60
栏目:
出版日期:
2022-07-15

文章信息/Info

Title:
Observation on Clinical Effects of Invigorating-spleen Removing-stasis Method in the Treatment of Stage Ⅲ/Ⅳ Gastric Cancer
作者:
贾英丽, 刘坤, 王英丽, 吴心力
黑龙江省中医药科学院，黑龙江 哈尔滨 150036
Author(s):
JIA Yingli, XU Yueze, LIU Kun, WANG Yingli
Heilongjiang Provincial Academy of Traditional Chinese Medicine, Harbin 150036, China
关键词:
胃癌; Ⅲ/Ⅳ期; 平消胶囊; 健脾祛瘀法; 临床观察
Keywords:
gastric cancer; stage Ⅲ/Ⅳ; capsules; invigorating-spleen removing-stasis method; clinical observation
分类号:
R256.3
DOI:
10.12174/j.issn.2096-9600.2022.07.15
文献标志码:
B
摘要:
目的观察健脾祛瘀法治疗Ⅲ/Ⅳ期脾胃虚弱、血瘀内阻证胃癌的临床疗效。 方法将48例胃癌Ⅲ/Ⅳ期脾胃虚弱、血瘀内阻证患者按随机数字表法分为观察组和对照组各24例，观察组口服健脾祛瘀方汤剂，每日1剂，对照组口服平消胶囊，每次4粒，每日3次，1个月1个疗程，连服2个疗程后观察两组患者治疗前后中医症状积分、卡劳夫斯基（Karnofsky）行为状况评分与肿瘤标志物改善情况。 结果治疗后观察组患者中医症状改善均优于治疗前及对照组治疗后，差异有统计学意义（P＜0.05）；体力状况改善优于对照组，差异有统计学意义（P＜0.05）；治疗后观察组肿瘤标志物癌胚抗原（carcinoembryonic antigen，CEA)、糖类抗原199(carbohydrate antigen-199，CA199)水平低于治疗前及对照组治疗后（P＜0.05），糖类抗原125(carbohydrate antigen-125，CA125)低于治疗前（P＜0.05），但与对照组治疗后比较差异无统计学意义（P＞0.05）。 结论健脾祛瘀方能改善Ⅲ/Ⅳ期脾胃虚弱、血瘀内阻证胃癌患者的中医症状及体力状况，抑制肿瘤标志物水平，效果优于平消胶囊。
Abstract:
ObjectiveTo observe clinical effects of invigorating-spleen removing-stasis method in treating stage Ⅲ/Ⅳ gastric cancer of spleen and stomach deficiency and blood stasis internal obstruction pattern. MethodsAll 48 patients were allocated to the observation group and the control group according to random number table method, with 24 cases in each group, the observation group took invigorating-spleen removing-stasis decoction, one dose each day, and the control group received Pingxiao capsules orally, four pills each time, three times each day, one month was one course of the treatment, after two courses of the treatment, to observe the improvements of TCM syndrome scores, Karnofsky behavioral state scores and tumor markers before and after the intervention between both groups. ResultsAfter the treatment, the improvements of TCM symptoms the improve ments of physical conditions of the observation group were better than these before treating, and these of the control group after treatment, and the difference had statistical meaning (P<0.05); were superior to these of the control group, and the difference had statistical meaning (P<0.05); after the treatment, the levels of tumor markers CEA and CA199 of the observation group were lower than these before treatment, and these of the control group after treatment (P<0.05), the level of CA125 was lower than that before treatment (P<0.05), the difference had no statistical meaning when the observation group was compared with the control group after treatment (P>0.05). ConclusionInvigorating-spleen removing-stasis prescription could improve TCM symptoms and physical conditions in the patients of stage Ⅲ/Ⅳ gastric cancer of spleen and stomach deficiency and blood stasis internal obstruction pattern, inhibit the levels of tumor markers, and its effects superior to these of Pingxiao capsules.

相似文献/References:

[1]熊墨年,唐晓玲,余炅,等.益气清毒法联合化疗治疗中晚期胃癌的临床观察[J].西部中医药,2011,24(11):35.
[2]张小仙,倪角角,陈辉.舒适护理在晚期胃癌患者中的应用[J].西部中医药,2012,25(12):105.
　ZHANG Xiao-xian,NI Jiao-jiao,CHEN Hui.Application of Comfort Care to the Patients with Gastric Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2012,25(07):105.
[3]王宏伟,程小丽,许雅清,等.苦马豆素对胃癌细胞中pten和survivin mRNA表达的影响[J].西部中医药,2015,28(12):25.
[4]胡玥,刘沈林.刘沈林教授“胃肾同治”理论探讨及其在胃癌中的应用[J].西部中医药,2015,28(10):72.
[5]朱剑梅,李世军.莲芪胶囊配合化疗治疗胃癌的临床研究[J].西部中医药,2015,28(12):91.
[6]李雅娟.围手术期护理对胃癌根除术患者护理质量的影响[J].西部中医药,2012,25(12):113.
　LI Ya-juan.Influence of Perioperative Care on Nursing Quality of Patients Undergoing Radical Resection of Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2012,25(07):113.
[7]刘河,刘超,杨世勇.胃癌中医证型与病灶组织中MMP-9、TIMP-2和HER-2表达的相关性分析[J].西部中医药,2017,30(02):134.
　LIU He,LIU Chao,YANG Shiyong.Correlation Analysis btween TCM Syndrome of Gastric Cancer and the Expression of MMP-9, TIMP-2 and HER-2 in Focus Tissue[J].Western Journal of Traditional Chinese Medicine,2017,30(07):134.
[8]王志新,邹玺,胡守友.中药抗胃癌的现代药理机制[J].西部中医药,2016,29(04):137.
　WANG Zhixin,ZOU Xi,HU Shouyou.Modern Pharmacological Mechanism of Herbs Fighting against Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2016,29(07):137.
[9]白兆琴,王惠霞,王宏伟△.黄芩苷对胃癌SGC-7901细胞TLR8、HIF-1α、PDGFβ和pten表达的影响[J].西部中医药,2017,30(08):12.
　BAI Zhaoqin,WANG Huixia,WANG Hongwei.The Effects of Baicalin on the Expression of TLR8, HIF-1α, PDGFβ and pten of Gastric Cancer SGC-7901 Cells[J].Western Journal of Traditional Chinese Medicine,2017,30(07):12.
[10]王亚峰,谢亲建,丁晓煜,等.白刺对胃癌MGC-803细胞的抑制作用[J].西部中医药,2018,31(05):14.
　WANG Yafeng,XIE Qinjian,DING Xiaoyu,et al.Study of Inhibitory Action of BaiCi on Gastric Cancer MGC-803 Cells[J].Western Journal of Traditional Chinese Medicine,2018,31(07):14.

备注/Memo

备注/Memo:
贾英丽（1972—），女，硕士学位，主任医师。研究方向：肺癌、消化道肿瘤、妇科肿瘤及内科常见病的中西医结合治疗。黑龙江省中医药科研项目（ZHY18-046）。
更新日期/Last Update: 2022-07-15